Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 3 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 11633480

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  2. US 11633479

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Apr 25, 2023 · Expires Apr 20, 2043

    granted

  3. US 11612657

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Mar 28, 2023 · Expires Mar 23, 2043

    granted

  4. US 11590229

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Feb 28, 2023 · Expires Feb 23, 2043

    granted

  5. US 11549109

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Jan 10, 2023 · Expires Jan 5, 2043

    granted

  6. US 11530408

    Therapeutic compositions

    Alnylam Pharmaceuticals, Inc. · Granted Dec 20, 2022 · Expires Dec 15, 2042

    granted

  7. US 11525138

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Dec 13, 2022 · Expires Dec 8, 2042

    granted

  8. US 11504391

    Modified RNA agents with reduced off-target effect

    Alnylam Pharmaceuticals, Inc. · Granted Nov 22, 2022 · Expires Nov 17, 2042

    granted

  9. US 11492623

    Hepatitis B virus (HBV) dsRNA agent compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Nov 8, 2022 · Expires Nov 3, 2042

    granted

  10. US 11446380

    Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression

    Alnylam Pharmaceuticals, Inc. · Granted Sep 20, 2022 · Expires Sep 15, 2042

    granted

  11. US 11434487

    Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 6, 2022 · Expires Sep 1, 2042

    granted

  12. US 11427822

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 30, 2022 · Expires Aug 25, 2042

    granted

  13. US 11419942

    Angiotensinogen (AGT) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Aug 23, 2022 · Expires Aug 18, 2042

    granted

  14. US 11406716

    Modified RNAi agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted

  15. US 11408001

    Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Aug 9, 2022 · Expires Aug 4, 2042

    granted

  16. US 11400158

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  17. US 11401517

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Aug 2, 2022 · Expires Jul 28, 2042

    granted

  18. US 11382979

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted

  19. US 11332743

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 17, 2022 · Expires May 12, 2042

    granted

  20. US 11326166

    Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  21. US 11324820

    Methods for the treatment of subjects having a hepatitis b virus (HBV) infection

    Alnylam Pharmaceuticals, Inc. · Granted May 10, 2022 · Expires May 5, 2042

    granted

  22. US 11319539

    Xanthine dehydrogenase (XDH) IRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 3, 2022 · Expires Apr 28, 2042

    granted

  23. US 11312957

    Modified iRNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Apr 26, 2022 · Expires Apr 21, 2042

    granted

  24. US 11306314

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 19, 2022 · Expires Apr 14, 2042

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.